Success Metrics

Active Trials
9(82%)

Phase Distribution

Ph phase_3
4
36%
Ph phase_1
7
64%

Phase Distribution

7

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
7(63.6%)
Phase 3Large-scale testing
4(36.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

9

trials recruiting

Total Trials

11

all time

Status Distribution
Active(11)

Detailed Status

Recruiting6
Active, not recruiting3
Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
11
Active
9
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 17 (63.6%)
Phase 34 (36.4%)

Trials by Status

active_not_recruiting327%
not_yet_recruiting218%
recruiting655%

Recent Activity

9 active trials
Showing 5 of 11
not_yet_recruitingphase_3

A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer

NCT07739758
recruitingphase_3

A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy

NCT07487896
active_not_recruitingphase_1

A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors

NCT06394414
recruitingphase_1

A Study of YL201 in Patients With Advanced Solid Tumors

NCT05434234
recruitingphase_1

A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors

NCT07208773
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT07739758Phase 3

A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer

Not Yet Recruiting
NCT07487896Phase 3

A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy

Recruiting
NCT06394414Phase 1

A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors

Active Not Recruiting
NCT05434234Phase 1

A Study of YL201 in Patients With Advanced Solid Tumors

Recruiting
NCT07208773Phase 1

A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors

Recruiting
NCT07407933Phase 1

A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

Recruiting
NCT06612151Phase 3

A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer

Active Not Recruiting
NCT06898957Phase 1

Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)

Active Not Recruiting
NCT07307053Phase 1

Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)

Not Yet Recruiting
NCT07258979Phase 1

A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.

Recruiting
NCT06629597Phase 3

A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma

Recruiting

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11